Clinical trials are a very important part of the research process. New treatments, medications and medical devices cannot be approved for use in Australia without going through clinical trials. Find out more about clinical trials.
ANAVEX®2-73 for mild cognitive impairment or early Alzheimer’s disease
A clinical trial that aims to assess the safety and efficacy of a new drug (ANAVEX®2-73) for the treatment of early Alzheimer’s disease.
Anti-tau treatment for early Alzheimer’s dementia
This study is investigating the effectiveness of medication JNJ-63733657 in delaying the progression of Alzheimer’s dementia by reducing the propagation of tau proteins.
Deferiprone as a treatment for Alzheimer’s disease
A clinical trial to investigate whether deferiprone delays dementia progression in the early stages of dementia.
Experimental treatment for Parkinson’s disease
This is a study of an experimental treatment (referred to as “study drug”) called CVL-751 as a possible treatment for Parkinson’s disease.
New potential treatment for adult males with Tourette Syndrome
A study to evaluate the safety and efficacy of new drug in male patients aged 18 to 50 with Tourette Syndrome (TS).
Possible treatment for Parkinson’s disease
Cerevel Therapeutics has begun a study of an experimental drug called CVL-751 as a possible treatment for people with Parkinson’s disease.
PRAX-944 as a potential treatment for essential tremor
A clinical trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of PRAX-944 in adults with essential tremor.
Sailuotong for vascular dementia or Alzheimer’s disease with cerebrovascular disease
A clinical study that is testing a new herbal medicine formula treatment for vascular dementia or Alzheimer’s disease with cerebrovascular disease.
Vagus nerve stimulation (VNS) device for the treatment of epilepsy
This post-market study involves collecting information for an already approved VNS device to get detailed information about the outcomes of people receiving the approved treatment.
WVE-003 in patients with Huntington’s disease
A multicentre, randomised, double-blind, placebo-controlled, phase 1b/2a study of WVE-003 in patients with Huntington’s disease.